Mupadolimab CPI-006|cas:2451856-97-4|西域试剂

Mupadolimab CPI-006,99.43%

产品编号：Bellancom-P99181| CAS NO：2451856-97-4

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99181	￥3000.00	杭州北京（现货）
Bellancom-P99181	￥6600.00	杭州北京（现货）
Bellancom-P99181	￥10600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Mupadolimab CPI-006

产品介绍

Mupadolimab (CPI-006) 是一种 IgG1κ 人源化的 FcγR 结合缺陷抗 CD73 单抗，激活 CD73^POS B 细胞。

生物活性

Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73^POS B cells.

体外研究

Mupadolimab induces the increased expression of markers associated with B cell maturation and antigen presentation, morphologic transformation to plasmablasts, and increased secretion of IgM and IgG.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Mupadolimab (10 mg/kg; i.p.; daily for 15 days) stimulates antigen specific humoral immunity in SARS-CoV-2 infected NSG-SGM3 mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NSG-SGM3 mice, immunized with an emulsion of 50 μg full length spike protein from SARS-CoV-2 and Freund’s Incomplete Adjuvant subcutaneously on both the left and right flank (25 μg/side)
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection, daily for 15 days
Result:	Mice treated with the drug made antibodies to the immunizing TS protein; but not to the control nucleocapsid SARS-CoV-2 viral protein.

体内研究

Mupadolimab (10 mg/kg; i.p.; daily for 15 days) stimulates antigen specific humoral immunity in SARS-CoV-2 infected NSG-SGM3 mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NSG-SGM3 mice, immunized with an emulsion of 50 μg full length spike protein from SARS-CoV-2 and Freund’s Incomplete Adjuvant subcutaneously on both the left and right flank (25 μg/side)
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection, daily for 15 days
Result:	Mice treated with the drug made antibodies to the immunizing TS protein; but not to the control nucleocapsid SARS-CoV-2 viral protein.